Online Articles: Clinical and Laboratory ObservationsSARS-CoV-2 Infection During Induction Chemotherapy in a Child With High-risk T-Cell Acute Lymphoblastic LeukemiaDantonello, Tobias M. MD*; Kartal-Kaess, Mutlu MD*; Aebi, Christoph MD, PhD†; Suter-Riniker, Franziska PhD‡; Busch, Jasmin D. MD§; Kubetzko, Susanne PhD∥; Bourquin, Jean-Pierre MD, PhD∥; Roessler, Jochen MD* Author Information *Division of Pediatric Hematology and Oncology †Division of Pediatric Infectiology, Department of Pediatrics §Department of Diagnostic, Interventional and Pediatric Radiology, Bern University Hospital ‡Institute for Infectious Diseases, University of Bern, Bern ∥Division of Oncology and Children’s Research Centre, University Children’s Hospital Zurich, Zurich, Switzerland The authors declare no conflict of interest. Reprints: Tobias M. Dantonello, MD, Division of Pediatric Hematology and Oncology, Department of Pediatrics, Bern University Hospital, Freiburgstrasse 10, Bern CH-3010, Switzerland (e-mail: [email protected]). Journal of Pediatric Hematology/Oncology 43(6):p e804-e807, August 2021. | DOI: 10.1097/MPH.0000000000001943 Buy Metrics Abstract The clinical course of SARS-CoV-2 infection (COVID-19) in children with hematologic malignancies is unclear. We describe the diagnosis, treatment and outcome of a 4-year-old boy with high-risk acute lymphoblastic leukemia and COVID-19. Regardless of immunosuppressive induction chemotherapy his symptoms remained moderate. He received only supportive treatment. Seroconversion occurred in a similar period as in immunocompetent adults. Despite prolonged myelosuppression he did neither acquire secondary infections nor did the treatment delay caused by the infection have a measurable negative impact on the residual disease of acute lymphoblastic leukemia. Intriguingly, residual leukemia even decreased even though he did not receive any antileukemic therapy. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.